Toxoplasmosis: epidemiologic study of hospitalizated cases in Spain (2000-2021)
DOI:
https://doi.org/10.4321/s2173-92772023000300002Keywords:
Human toxoplasmosis; Toxoplasma gondii; hospitalizationAbstract
Introduction: Toxoplasmosis is a worldwide zoonotic disease caused by Toxoplasma gondii. Humans are intermediate hosts within a multispecies cycle in which felids are definitive hosts. The importance of the human infection is restricted to immunocompromised individuals and pregnant women who can transmit the disease to the fetus. The purpose was to describe toxoplasmosis hospitalization epidemiology in Spain during 2000-2021.
Methods: A descriptive analysis of hospitalization in Spain with a diagnosis of toxoplasmosis from 2000 to 2021 was performed using data from the Specialized Health Care Registry (RAE-CMBD). The variables analyzed were sex, age and Autonomous Communities (CCAA).
Results: During the period 2000-2021 there were 8,102 hospital admissions with a diagnosis of toxoplasmosis (hospitalization rate HT = 0.81). This HT decreased throughout the period, from 1.55 (2000) to 0.48 in 2021. The number of admissions was higher in men and in these, there has been a steeper decline over the period. The age group with the highest accumulated HT was 35-39 years old (HT=1.96). The CCAA with the highest total HT were Ceuta, Melilla, Balearic Islands and Catalonia.
Conclusions: HT toxoplasmosis have progressively decresed throughout 2000-2021. This decrease is more pronounced in men and is due, above all, to the decrease in HT in 35-39 age group.
Downloads
References
Aguirre AA, Longcore T, Barbieri M, Dabritz H, Hill D, Klein PN, Lepczyk C, Lilly EL, McLeod R, Milcarsky J, Murphy CE, Su C, VanWormer E, Yolken R, Sizemore GC. “The One Health Approach to Toxoplasmosis: Epidemiology, Control, and Prevention Strategies”. Ecohealth. 2019 Jun;16(2):378-390. doi: 10.1007/s10393-019-01405-7. Epub 2019 Apr 3. Erratum in: Ecohealth. 2019 Jun 5;: PMID: 30945159; PMCID: PMC6682582.
Smith NC, Goulart C, Hayward JA, Kupz A, Miller CM, van Dooren GG. “Control of human toxoplasmosis”. Int J Parasitol. 2021 Feb;51(2-3):95-121. doi: 10.1016/j.ijpara.2020.11.001. Epub 2020 Dec 19. PMID: 33347832.
European Food Safety Authority, European Centre for Disease Prevention and Control. “The European Union One Health 2021 Zoonoses Report”. EFSA Journal. 2022;20(12). Dot: 10.2903/j.efsa.2022.7666
Zhou Z, Ortiz Lopez HIA, Pérez GE, Burgos LM, Farina JM, Saldarriaga C, Lopez-Santi R, Cotella JI, Pérez ALS, Baranchuk A. “Toxoplasmosis and the Heart”. Curr Probl Cardiol. 2021 Mar;46(3):100741. doi: 10.1016/j.cpcardiol.2020.100741. Epub 2020 Nov 2. PMID: 33183832.
Noogareda F, Le Strat Y, Villena I, De Valk H, Goulet V. “Incidence and prevalence of Toxoplasma gondii infection in women in France, 1980-2020: model-based estimation”. Epidemiol Infect. 2014 Aug;142(8):1661-70. doi: 10.1017/S0950268813002756.
Flegr J, Prandota J, Sovicková M, Israili ZH. “Toxoplasmosis--a global threat. Correlation of latent toxoplasmosis with specific disease burden in a set of 88 countries”. PLoS One. 2014 Mar 24;9(3):e90203. doi: 10.1371/journal.pone.0090203.
Pereira KS, Franco RMB, Leal DAG. Chapter 1 – “Transmission of Toxoplasmosis (Toxoplasma gondii) by Foods”, Editor(s): Steve L. Taylor. En: Taylor SL, editor. Advances in Food and Nutrition Research. Academic Press; 2010; 60:1-19. doi: 10.1016/S1043-4526(10)60001-0.
Protocolo de la Red de Vigilancia Epidemiológica de Toxoplasmosis Congénita. Protocolos de la Red Nacional de Vigilancia Epidemiológica. Instituto de Salud Carlos III. Junio, 2015; 604-612.
Barsoum RS. “Parasitic infections in transplant recipients”. Nat Clin Pract Nephrol. 2006;2(9):490–503. doi: 10.1038/ncpneph0255
Stelzer S, Basso W, Benavides Silván J, Ortega-Mora LM, Maksimov P, Gethmann J, Conraths FJ, Schares G. “Toxoplasma gondii infection and toxoplasmosis in farm animals: Risk factors and economic impact”. Food Waterborne Parasitol. 2019;15:e00037. doi: 10.1016/j.fawpar.2019.e00037.
Kalogeropoulos D, Sakkas H, Mohammed B, Vartholomatos G, Malamos K, Sreekantam S, Kanavaros P, Kalogeropoulos C. “Ocular toxoplasmosis: a review of the current diagnostic and therapeutic approaches”. Int Ophthalmol. 2022 Jan;42(1):295-321. doi: 10.1007/s10792-021-01994-9. Epub 2021 Aug 9. PMID: 34370174; PMCID: PMC8351587.
Yan J, Huang B, Liu G, Wu B, Huang S, Zheng H, Shen J, Lun ZR, Wang Y, Lu F. “Meta-analysis of prevention and treatment of toxoplasmic encephalitis in HIV-infected patients”. Acta Trop. 2013 Sep;127(3):236-44. doi: 10.1016/j.actatropica.2013.05.006. Epub 2013 May 23. PMID: 237076
Le LT Spudich. “HIV HIV-Associated Neurologic Disorders and Central Nervous System Opportunistic Infections in HIV”. Semin Neurol, 2016;36(4):373-81. doi: 10.1055/s-0036-1585454.
Milne GC, Webster JP, Walker M. “Is the incidence of congenital toxoplasmosis declining?” Trends Parasitol. 2023;39(1):26–37. doi: 10.1016/j.pt.2022.10.003
Rostami A, Riahi SM, Gamble HR, Fakhri Y, Nourollahpour Shiadeh M, Danesh M, Behniafar H, Paktinat S, Foroutan M, Mokdad AH, Hotez PJ, Gasser RB. “Global prevalence of latent toxoplasmosis in pregnant women: a systematic review and meta-analysis”. Clin Microbiol Infect. 2020 Jun;26(6):673-683. doi: 10.1016/j.cmi.2020.01.008. Epub 2020 Jan 20. PMID: 31972316.
European Centre for Disease Prevention and Control. Congenital toxoplasmosis. In: ECDC. Annual epidemiological report for 2019. Stockholm: ECDC; 2021
Menchi-Elanzi M, Mayoral AM, Morales J, Pinargote-Celorio H, González-Alcaide G, Ramos-Rincón JM. “Toxoplasma gondii infection in hospitalized people living with HIV in Spain, 1997 to 2015”. Parasitol Res. 2021 Feb;120(2):755-761. doi: 10.1007/s00436-020-07007-5.
Soriano V, Ramos J M, Barreiro P, Fernandez-Montero J V. “5AIDS Clinical Research in Spain-Large HIV Population, Geniality of Doctors, and Missing Opportunities”. Viruses, 2018;10(6):293.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 María González-Viadero , Raquel Barba-Sánchez, David González-Barrio , Isabel Fuentes-Corripio , Rosa Mª Estévez-Reboredo
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
El material creado por un autor puede ser distribuido, copiado y exhibido por terceros si se hace referencia a la autoría. No se puede obtener ningún beneficio comercial y las obras derivadas tienen que estar bajo los mismos términos de licencia que el trabajo original
